Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study

Authors: Mona Rafik Loutfy, Sharon Lynn Walmsley, Marina Barbara Klein, Janet Raboud, Alice Lin-in Tseng, Sandra Lauren Blitz, Neora Pick, Brian Conway, Jonathan Benjamin Angel, Anita Rochelle Rachlis, Kevin Gough, Jeff Cohen, David Haase, David Burdge, Fiona Mary Smaill, Alexandra de Pokomandy, Hugues Loemba, Sylvie Trottier, Charles Jean la Porte

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Although some studies show higher antiretroviral concentrations in women compared to men, data are limited. We conducted a cross-sectional study of HIV-positive women to determine if protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) Cmin and Cmax values were significantly different than historical general population (predominantly male) averages and to evaluate correlates of higher concentrations.

Methods

HIV-positive women with virologic suppression (viral load < 50copies/mL) on their first antiretroviral regimen were enrolled. Timed blood samples for Cmin and Cmax were drawn weekly for 3 weeks. The ratio of each individual’s median Cmin and Cmax to the published population mean values for their PI or NNRTI was calculated and assessed using Wilcoxon sign-rank. Intra- and inter-patient variability of antiretroviral drug levels was assessed using coefficient of variation and intra-class correlation. Linear regression was used to identify correlates of the square root-transformed Cmin and Cmax ratios.

Results

Data from 82 women were analyzed. Their median age was 41 years (IQR=36-48) and duration of antiretrovirals was 20 months (IQR=9-45). Median antiretroviral Cmin and Cmax ratios were 1.21 (IQR=0.72-1.89, p=0.003) (highest ratios for nevirapine and lopinavir) and 0.82 (IQR=0.59-1.14, p=0.004), respectively. Nevirapine and efavirenz showed the least and unboosted atazanavir showed the most intra- and inter-patient variability. Higher CD4+ count correlated with higher Cmin. No significant correlates for Cmax were found.

Conclusions

Compared to historical control data, Cmin in the women enrolled was significantly higher whereas Cmax was significantly lower. Antiretroviral Cmin ratios were highly variable within and between participants. There were no clinically relevant correlates of drug concentrations.

Trial registration

Appendix
Available only for authorised users
Literature
1.
go back to reference Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998, 338 (13): 853-860. 10.1056/NEJM199803263381301.CrossRefPubMed Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998, 338 (13): 853-860. 10.1056/NEJM199803263381301.CrossRefPubMed
2.
go back to reference Zeldin RK, Petruschke RA: Pharmacologic and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004, 53 (1): 4-9.CrossRefPubMed Zeldin RK, Petruschke RA: Pharmacologic and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004, 53 (1): 4-9.CrossRefPubMed
4.
go back to reference Montessori V, Press N, Harris M, Akagi L, Montaner JS: Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J. 2004, 170 (2): 229-238. Montessori V, Press N, Harris M, Akagi L, Montaner JS: Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J. 2004, 170 (2): 229-238.
5.
go back to reference Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M: Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005–2008. Arch Int Med. 2010, 170 (1): 57-65. 10.1001/archinternmed.2009.432.CrossRef Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M: Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005–2008. Arch Int Med. 2010, 170 (1): 57-65. 10.1001/archinternmed.2009.432.CrossRef
6.
go back to reference Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d’Arminio Monforte A, ICoNA Foundation Study Group: Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med. 2010, 11 (2): 104-13. 10.1111/j.1468-1293.2009.00750.x.CrossRefPubMed Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d’Arminio Monforte A, ICoNA Foundation Study Group: Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med. 2010, 11 (2): 104-13. 10.1111/j.1468-1293.2009.00750.x.CrossRefPubMed
7.
go back to reference Foisy MM, Gough K, Quan C, Harris K, Ibanez D, Phillips A: Hospitalization due to adverse drug reactions and drug interactions before and after HAART. Can J Inf Dis. 2000, 11 (4): 193-201. Foisy MM, Gough K, Quan C, Harris K, Ibanez D, Phillips A: Hospitalization due to adverse drug reactions and drug interactions before and after HAART. Can J Inf Dis. 2000, 11 (4): 193-201.
8.
go back to reference Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI: Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence:prospective observational study. Br J Clin Pharmacol. 2008, 65 (3): 396-406. 10.1111/j.1365-2125.2007.03034.x.CrossRefPubMed Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI: Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence:prospective observational study. Br J Clin Pharmacol. 2008, 65 (3): 396-406. 10.1111/j.1365-2125.2007.03034.x.CrossRefPubMed
9.
go back to reference Núñez MJ, Martín-Carbonero L, Moreno V, Valencia E, Garcia-Samaniego J, Castillo JG, Barreiro P, González-Lahoz J, Soriano V: Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses. 2006, 22 (9): 825-829. 10.1089/aid.2006.22.825.CrossRefPubMed Núñez MJ, Martín-Carbonero L, Moreno V, Valencia E, Garcia-Samaniego J, Castillo JG, Barreiro P, González-Lahoz J, Soriano V: Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses. 2006, 22 (9): 825-829. 10.1089/aid.2006.22.825.CrossRefPubMed
10.
go back to reference Núñez M: Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010, 52 (3): 1143-55. 10.1002/hep.23716.CrossRefPubMed Núñez M: Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010, 52 (3): 1143-55. 10.1002/hep.23716.CrossRefPubMed
11.
go back to reference Clark R: Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Safe. 2005, 28 (12): 1075-1083. 10.2165/00002018-200528120-00003.CrossRef Clark R: Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Safe. 2005, 28 (12): 1075-1083. 10.2165/00002018-200528120-00003.CrossRef
12.
go back to reference d’Arminio Monforte A, González L, Haberl A, Sherr L, Ssanyu-Sseruma W, Walmsley SL, Women for Positive Action: Better mind the gap:addressing the shortage of HIV-positive women in clinical trials. AIDS. 2010, 24 (8): 1091-1094. 10.1097/QAD.0b013e3283390db3.CrossRefPubMed d’Arminio Monforte A, González L, Haberl A, Sherr L, Ssanyu-Sseruma W, Walmsley SL, Women for Positive Action: Better mind the gap:addressing the shortage of HIV-positive women in clinical trials. AIDS. 2010, 24 (8): 1091-1094. 10.1097/QAD.0b013e3283390db3.CrossRefPubMed
13.
go back to reference Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J, The Women’s Interagency HIV Study: WIHS collaborative study group. Epidemiology. 1998, 9 (2): 117-125. 10.1097/00001648-199803000-00004.CrossRefPubMed Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J, The Women’s Interagency HIV Study: WIHS collaborative study group. Epidemiology. 1998, 9 (2): 117-125. 10.1097/00001648-199803000-00004.CrossRefPubMed
14.
go back to reference Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Günthard HF, Telenti A, Furrer H, Yerly S, Francioli P, Swiss HIV Cohort Study: Cohort: profile:the Swiss HIV cohort study. Int J Epidemiol. 2010, 39 (5): 1179-1189.CrossRefPubMed Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Günthard HF, Telenti A, Furrer H, Yerly S, Francioli P, Swiss HIV Cohort Study: Cohort: profile:the Swiss HIV cohort study. Int J Epidemiol. 2010, 39 (5): 1179-1189.CrossRefPubMed
15.
go back to reference Tran C, Knowles SR, Liu BA, Shear NH: Gender differences in adverse drug reactions. J Clin Pharmacol. 1998, 38 (11): 1003-1009. 10.1177/009127009803801103.CrossRefPubMed Tran C, Knowles SR, Liu BA, Shear NH: Gender differences in adverse drug reactions. J Clin Pharmacol. 1998, 38 (11): 1003-1009. 10.1177/009127009803801103.CrossRefPubMed
16.
go back to reference Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M: Sex issues in HIV-1-infected persons during highly active antiretroviral therapy:a systematic review. J Antimicrob Chemother. 2007, 60: 724-732. 10.1093/jac/dkm302.CrossRefPubMed Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M: Sex issues in HIV-1-infected persons during highly active antiretroviral therapy:a systematic review. J Antimicrob Chemother. 2007, 60: 724-732. 10.1093/jac/dkm302.CrossRefPubMed
17.
go back to reference Emery J, Pick N, Mills EJ, Cooper CL: Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients. Patient Prefer Adherence. 2010, 4: 97-103.PubMedPubMedCentral Emery J, Pick N, Mills EJ, Cooper CL: Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients. Patient Prefer Adherence. 2010, 4: 97-103.PubMedPubMedCentral
18.
go back to reference Viramune (nevirapine) Package insert. 2010, Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals, Inc Viramune (nevirapine) Package insert. 2010, Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals, Inc
19.
go back to reference Floridia M, Giuliano M, Palmisano L, Vella S: Gender differences in the treatment of HIV infection. Pharmacol Res. 2008, 58 (3–4): 173-182.CrossRefPubMed Floridia M, Giuliano M, Palmisano L, Vella S: Gender differences in the treatment of HIV infection. Pharmacol Res. 2008, 58 (3–4): 173-182.CrossRefPubMed
20.
go back to reference Umeh OC, Currier JS: Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Exper Opin Drug Metab Toxicol. 2006, 2 (2): 273-283. 10.1517/17425255.2.2.273.CrossRef Umeh OC, Currier JS: Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Exper Opin Drug Metab Toxicol. 2006, 2 (2): 273-283. 10.1517/17425255.2.2.273.CrossRef
21.
go back to reference Gandhi M, Aweeka F, Greenblatt RM, Blashke TF: Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004, 44: 499-523. 10.1146/annurev.pharmtox.44.101802.121453.CrossRefPubMed Gandhi M, Aweeka F, Greenblatt RM, Blashke TF: Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004, 44: 499-523. 10.1146/annurev.pharmtox.44.101802.121453.CrossRefPubMed
22.
go back to reference Ofotokun I, Chuck SK, Hitti JE: Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007, 4 (2): 106-119. 10.1016/S1550-8579(07)80025-8.CrossRefPubMed Ofotokun I, Chuck SK, Hitti JE: Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007, 4 (2): 106-119. 10.1016/S1550-8579(07)80025-8.CrossRefPubMed
23.
go back to reference Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM: Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004, 189 (7): 1176-1184. 10.1086/382754.CrossRefPubMed Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM: Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004, 189 (7): 1176-1184. 10.1086/382754.CrossRefPubMed
24.
go back to reference Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A: Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004, 48 (11): 4256-4262. 10.1128/AAC.48.11.4256-4262.2004.CrossRefPubMedPubMedCentral Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A: Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004, 48 (11): 4256-4262. 10.1128/AAC.48.11.4256-4262.2004.CrossRefPubMedPubMedCentral
25.
go back to reference Dickinson L, Boffito M, Back DJ, Khoo SH, Pozniak AL, Mugyenyi P, Merry C, Autar RS, Burger DM, Aarons LJ: Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother. 2008, 62 (6): 1344-1355. 10.1093/jac/dkn399.CrossRefPubMedPubMedCentral Dickinson L, Boffito M, Back DJ, Khoo SH, Pozniak AL, Mugyenyi P, Merry C, Autar RS, Burger DM, Aarons LJ: Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother. 2008, 62 (6): 1344-1355. 10.1093/jac/dkn399.CrossRefPubMedPubMedCentral
26.
go back to reference von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A: A comparison of the steady-stage pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol. 2006, 62 (5): 552-559. 10.1111/j.1365-2125.2006.02664.x.CrossRefPubMedPubMedCentral von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A: A comparison of the steady-stage pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol. 2006, 62 (5): 552-559. 10.1111/j.1365-2125.2006.02664.x.CrossRefPubMedPubMedCentral
27.
go back to reference Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, Meneghetti G, Maserati R: Sex differences in nevirapine disposition in HIV-infected patients. AIDS. 2003, 17 (16): 2399-2400. 10.1097/00002030-200311070-00018.CrossRefPubMed Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, Meneghetti G, Maserati R: Sex differences in nevirapine disposition in HIV-infected patients. AIDS. 2003, 17 (16): 2399-2400. 10.1097/00002030-200311070-00018.CrossRefPubMed
28.
go back to reference Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijenen JH, Huitema AD, 2NN study group: Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivi Ther. 2005, 10 (1): 145-55. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijenen JH, Huitema AD, 2NN study group: Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivi Ther. 2005, 10 (1): 145-55.
29.
go back to reference Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K, GRACE (Gender, Race, And Clinical Experience) Study Group: Sex-based outcomes of darunavir-ritonavir therapy:a single-group trial. Ann Intern Med. 2010, 153 (6): 349-357. 10.7326/0003-4819-153-6-201009210-00002.CrossRefPubMedPubMedCentral Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K, GRACE (Gender, Race, And Clinical Experience) Study Group: Sex-based outcomes of darunavir-ritonavir therapy:a single-group trial. Ann Intern Med. 2010, 153 (6): 349-357. 10.7326/0003-4819-153-6-201009210-00002.CrossRefPubMedPubMedCentral
31.
go back to reference Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000, 12 (3): 255-266. 10.1080/09540120050042891.CrossRefPubMed Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000, 12 (3): 255-266. 10.1080/09540120050042891.CrossRefPubMed
32.
go back to reference Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, Weissman S, Neidig J, Marcus C, Chesney M, Cohn SE, Wu AW, Adult AIDS Clinical Trials Unit Outcomes Committee: Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001, 54: S77-S90. 10.1016/S0895-4356(01)00449-8.CrossRefPubMed Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, Weissman S, Neidig J, Marcus C, Chesney M, Cohn SE, Wu AW, Adult AIDS Clinical Trials Unit Outcomes Committee: Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001, 54: S77-S90. 10.1016/S0895-4356(01)00449-8.CrossRefPubMed
33.
go back to reference Reyataz (atazanavir sulfate) Package insert. 2010, Princeton, NJ, USA: Bristol-Myers Squibb Company Reyataz (atazanavir sulfate) Package insert. 2010, Princeton, NJ, USA: Bristol-Myers Squibb Company
34.
go back to reference Kaletra (lopinavir/ritonavir) Package insert. 2010, North Chicago, IL, USA: Abbott Laboratories Kaletra (lopinavir/ritonavir) Package insert. 2010, North Chicago, IL, USA: Abbott Laboratories
35.
go back to reference Sustiva (efavirenz) Package insert. 2010, Princeton, NJ, USA: Bristol-Myers Squibb Company Sustiva (efavirenz) Package insert. 2010, Princeton, NJ, USA: Bristol-Myers Squibb Company
36.
go back to reference van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM: The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000, 14 (8): F77-82. 10.1097/00002030-200005260-00001.CrossRefPubMed van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM: The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000, 14 (8): F77-82. 10.1097/00002030-200005260-00001.CrossRefPubMed
37.
go back to reference Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P: Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med. 2009, 10 (9): 548-554. 10.1111/j.1468-1293.2009.00725.x.CrossRefPubMed Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P: Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med. 2009, 10 (9): 548-554. 10.1111/j.1468-1293.2009.00725.x.CrossRefPubMed
38.
go back to reference Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, Carson KA, Siliciano RF, Flexner C: Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006, 42 (8): 1189-1196. 10.1086/501458.CrossRefPubMed Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, Carson KA, Siliciano RF, Flexner C: Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006, 42 (8): 1189-1196. 10.1086/501458.CrossRefPubMed
39.
go back to reference Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, Delavarga M, Fumaz CR, Barbanoj MJ, Clotet B: Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Brit J Clin Pharmoco. 2007, 63 (6): 715-721. 10.1111/j.1365-2125.2006.02834.x.CrossRef Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, Delavarga M, Fumaz CR, Barbanoj MJ, Clotet B: Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Brit J Clin Pharmoco. 2007, 63 (6): 715-721. 10.1111/j.1365-2125.2006.02834.x.CrossRef
40.
go back to reference Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J, ATHENA Cohort Study Group: Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naïve-HIV-1-infected individuals. AIDS. 2003, 17 (8): 1157-1165. 10.1097/00002030-200305230-00007.CrossRefPubMed Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J, ATHENA Cohort Study Group: Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naïve-HIV-1-infected individuals. AIDS. 2003, 17 (8): 1157-1165. 10.1097/00002030-200305230-00007.CrossRefPubMed
41.
go back to reference Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV Cohort Study: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1:a pharmacogenetics study. Lancet. 2002, 359 (9300): 30-36. 10.1016/S0140-6736(02)07276-8.CrossRefPubMed Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV Cohort Study: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1:a pharmacogenetics study. Lancet. 2002, 359 (9300): 30-36. 10.1016/S0140-6736(02)07276-8.CrossRefPubMed
42.
go back to reference Wegner S, Vahey M, Dolan M, Wallace M, Aronson N, Barile A, Emmons W, Frazier S, Stephan K, Nau M, Piscitelli S, Harrigan R, Larder B: Racial Differences in Clinical Efficacy of Efavirenz-Based Antiretroviral Therapy [abstract]. 2002, Seattle, WA, USA: 9th Conference on Retroviruses and Opportunistic Infections, 24-28. Abstract 429-W Wegner S, Vahey M, Dolan M, Wallace M, Aronson N, Barile A, Emmons W, Frazier S, Stephan K, Nau M, Piscitelli S, Harrigan R, Larder B: Racial Differences in Clinical Efficacy of Efavirenz-Based Antiretroviral Therapy [abstract]. 2002, Seattle, WA, USA: 9th Conference on Retroviruses and Opportunistic Infections, 24-28. Abstract 429-W
43.
go back to reference Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA: Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS. 2001, 15 (8): 991-998. 10.1097/00002030-200105250-00007.CrossRefPubMed Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA: Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS. 2001, 15 (8): 991-998. 10.1097/00002030-200105250-00007.CrossRefPubMed
44.
go back to reference Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang’a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL: MDR1 pharmacogenetics:frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001, 11: 217-221. 10.1097/00008571-200104000-00005.CrossRefPubMed Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang’a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL: MDR1 pharmacogenetics:frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001, 11: 217-221. 10.1097/00008571-200104000-00005.CrossRefPubMed
45.
go back to reference Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001, 358 (9279): 383-384. 10.1016/S0140-6736(01)05579-9.CrossRefPubMed Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001, 358 (9279): 383-384. 10.1016/S0140-6736(01)05579-9.CrossRefPubMed
46.
go back to reference Prezista (darunavir). Package insert (2010). Toronto, ON, Canada: Janssen Inc Prezista (darunavir). Package insert (2010). Toronto, ON, Canada: Janssen Inc
47.
go back to reference Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A: Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother. 2009, 64 (1): 109-117. 10.1093/jac/dkp132.CrossRefPubMed Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A: Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother. 2009, 64 (1): 109-117. 10.1093/jac/dkp132.CrossRefPubMed
48.
go back to reference Gibbons SE, Back DJ, Khoo SH: Is there evidence of age-dependent variation in lopinavir or efavirenz levels in female subjects in the clinical setting? [abstract]. 2005, Quebec City, QC, Canada: 6th International Workshop on Clinical Pharmacology of HIV Therapy, 28-30. Abstract 54 Gibbons SE, Back DJ, Khoo SH: Is there evidence of age-dependent variation in lopinavir or efavirenz levels in female subjects in the clinical setting? [abstract]. 2005, Quebec City, QC, Canada: 6th International Workshop on Clinical Pharmacology of HIV Therapy, 28-30. Abstract 54
Metadata
Title
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study
Authors
Mona Rafik Loutfy
Sharon Lynn Walmsley
Marina Barbara Klein
Janet Raboud
Alice Lin-in Tseng
Sandra Lauren Blitz
Neora Pick
Brian Conway
Jonathan Benjamin Angel
Anita Rochelle Rachlis
Kevin Gough
Jeff Cohen
David Haase
David Burdge
Fiona Mary Smaill
Alexandra de Pokomandy
Hugues Loemba
Sylvie Trottier
Charles Jean la Porte
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-256

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.